Endometrial cancer is the most frequent gynecological malignancy, and, although
epidemiologically it mainly affects advanced age women, it can also affect young patients …

Endometrial carcinoma (EC) is traditionally treated with surgery and adjuvant treatment
depending on clinicopathological risk factors. The genomic analysis of EC in 2013 and …

Objective Despite its generally favorable prognosis at primary diagnosis, recurrence of
endometrial cancer remains an important clinical challenge. The aim of this study was to …

Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma
with secondary sarcomatous trans-differentiation (conversion theory). The clinical …

The treatment for endometrial cancer is rapidly evolving with the development of molecular
analysis and novel strategies. Surgical resection, cytotoxic chemotherapy, endocrine or …

Clear cell endometrial carcinoma represents an uncommon and poorly understood entity.
Data from molecular/genomic profiling highlighted the importance of various signatures in …

Selinexor is an oral inhibitor of the nuclear export protein called Exportin 1 (XPO1) with
demonstrated antitumor activity in hematological and solid tumors. Selinexor, blocking …

Endometrial cancer is the most common gynecological disease in developed countries.
Although it is considered an indolent disease, advanced and recurrent endometrial …

Cancer cells are usually featured by metabolic adaptations that facilitate their growth,
invasion, and metastasis. Thus, reprogramming of intracellular energy metabolism is …

Background and Objectives: Minimally invasive surgery (MIS) has recently increased its
application in the treatment of gynecological malignancies. Despite technological and …